Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Cancer

Sirtuin 1 (SIRT1); AMP-activated protein kinase (AMPK)

In vitro and mouse studies suggest activating SIRT1 or AMPK could help prevent hypoxia-induced chemotherapy resistance. In non-small cell lung cancer (NSCLC) cell lines, hypoxic conditions decreased AMPK activation, SIRT1 expression and response to the generic chemotherapeutics cisplatin or doxorubicin compared with normoxic conditions. In mice with NSCLC xenografts, a SIRT1 activator plus cisplatin decreased tumor volume more than cisplatin alone, but the effects of SIRT1 activation could be prevented by AMPK inhibition. Next steps could include testing in additional animal models of cancer.

SciBX 7(1); doi:10.1038/scibx.2014.10
Published online Jan. 9, 2014

Patent and licensing status unavailable

Shin, D.H. et al. Cancer Res.; published online Nov. 15, 2013;
doi:10.1158/0008-5472.CAN-13-2620
Contact: Jong-Wan Park, Seoul National University College of Medicine, Seoul, South Korea
e-mail:

parkjw@snu.ac.kr